PUBLISHER: The Business Research Company | PRODUCT CODE: 1945345
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945345
Immunohistochemistry (IHC) is a diagnostic technique that utilizes the interaction between antibodies and antigens to identify specific proteins and antigens within tissue sections. This interaction is visualized through chromogenic detection using enzyme-substrate or fluorescent detection using fluorescent dyes.
The main products associated with immunohistochemistry (IHC) include antibodies, equipment, reagents, and kits. Antibodies are proteins produced by the immune system to neutralize harmful antigens, and in the context of IHC, they are employed to detect the specific location of proteins or antigens for diagnostic purposes. The applications of IHC span diagnostics, drug testing, and other related areas, with end-users including hospitals, diagnostic laboratories, research institutes, and others.
Tariffs are influencing the immunohistochemistry market by increasing costs of imported antibodies, reagents, staining systems, slide scanners, and imaging components used in diagnostic and research workflows. Hospitals and diagnostic laboratories in North America and Europe are most affected due to dependence on imported high-quality antibodies and equipment, while Asia-Pacific faces cost pressures in reagent exports. These tariffs are raising operational costs and delaying equipment upgrades. However, they are also supporting local antibody production, regional reagent manufacturing, and domestic development of automated IHC systems.
The immunohistochemistry (ihc) market research report is one of a series of new reports from The Business Research Company that provides immunohistochemistry (ihc) market statistics, including immunohistochemistry (ihc) industry global market size, regional shares, competitors with a immunohistochemistry (ihc) market share, detailed immunohistochemistry (ihc) market segments, market trends and opportunities, and any further data you may need to thrive in the immunohistochemistry (ihc) industry. This immunohistochemistry (ihc) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The immunohistochemistry (ihc) market size has grown rapidly in recent years. It will grow from $2.76 billion in 2025 to $3.05 billion in 2026 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to growing use of ihc in cancer diagnostics, expansion of hospital pathology laboratories, increased availability of monoclonal antibodies, rising adoption of tissue-based diagnostics, growing clinical research activities.
The immunohistochemistry (ihc) market size is expected to see rapid growth in the next few years. It will grow to $4.47 billion in 2030 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to increasing demand for precision oncology diagnostics, rising adoption of ai-enabled pathology analysis, expansion of biomarker-driven drug development, growing use of multiplex tissue profiling, increasing investments in advanced pathology infrastructure. Major trends in the forecast period include increasing adoption of automated ihc staining systems, rising use of multiplex ihc techniques, growing integration of digital pathology platforms, expansion of companion diagnostic applications, enhanced focus on high-specificity antibodies.
The increasing demand for personalized medicines is anticipated to accelerate the growth of the immunohistochemistry (IHC) market in the coming years. Personalized medicine refers to a healthcare approach that customizes medical decisions, treatments, and products to individual patients based on their genetic makeup, environmental factors, and lifestyle attributes. Immunohistochemistry plays a crucial role in this approach by enabling the identification of specific protein biomarkers that support precise tumor classification and accurate diagnosis. For example, in February 2024, according to the Personalized Medicine Coalition, a United States-based non-profit research organization, personalized medicines represented more than one-third of all new approvals by the United States Food and Drug Administration in 2023. During the same year, the FDA approved 16 new personalized therapies for rare disease patients, compared to six approvals in 2022. As a result, the rising adoption of personalized medicines is contributing to the expansion of the immunohistochemistry market.
Major players in the immunohistochemistry (IHC) market are concentrating on improving diagnostic accuracy through innovative technologies and high-quality reagents to enhance tissue analysis effectiveness in various clinical and research contexts. The Neoflex multiomics mass spectrometry imaging (MSI) system is a cutting-edge imaging platform tailored for precise tissue analysis, enabling researchers to progress from discovery to clinical applications using high-resolution mass spectrometry techniques, especially for spatially mapping biomolecules in tissues. For example, in June 2024, Bruker Corporation, a US-based company that develops and manufactures scientific instruments along with analytical and diagnostic solutions, introduced its matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF/TOF) Neoflex Imaging Profiler for mass spectrometry-based tissue imaging. The Neoflex MSI system addresses the demand for advancing from discovery imaging to clinical tissue research. It incorporates Bruker's 10-kHz smartbeam 3D laser, improved imaging detectors, and supports OME-TIFF file output with SCiLS Scope software.
In December 2023, Danaher Corporation, a United States-based life sciences and diagnostics company, acquired Abcam plc for an undisclosed value. Through this acquisition, Danaher sought to broaden its portfolio of life science reagents and consumables, strengthen its protein analysis tools for both research and diagnostic applications, accelerate growth across the life sciences ecosystem, and enhance its global presence by offering more integrated solutions to researchers and healthcare professionals. Abcam plc is a United Kingdom-based biotechnology company specializing in antibodies, reagents, assays, and immunohistochemistry products.
Major companies operating in the immunohistochemistry (ihc) market are Thermo Fisher Scientific Inc., F. Hoffmann-La Roche AG, Merck Group, Danaher Corporation, PerkinElmer Inc., Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., Bio SB Inc., Agilent Technologies Inc., Abcam plc, Takara Bio Inc., Biocare Medical LLC, Bio-Genex Laboratories, Diagnostic BioSystems Inc., PHC Holdings Corporation, Leica Biosystems, Vector Laboratories, Ionpath Inc., Reveal Biosciences, Akrivis Technologies Private Limited, LifeSpan BioSciences Inc., Enzo Life Sciences Inc., Epitomics Inc., GenScript Biotech
North America was the largest region in the immunohistochemistry (IHC) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the immunohistochemistry (IHC) market report during the forecast period. The regions covered in the immunohistochemistry (ihc) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the immunohistochemistry (ihc) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The immunohistochemistry (IHC) market consists of sales of primary antibodies, slide staining system, tissue microarrays, tissue processing systems, slide scanners secondary antibodies, histological stains, blocking sera and reagents, chromogenic substrates, fixation reagents and stabilizers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Immunohistochemistry (IHC) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses immunohistochemistry (ihc) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for immunohistochemistry (ihc) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The immunohistochemistry (ihc) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.